NCT03387254

Brief Summary

The aim of this study is to assess feasibility, acceptability and efficacy of two VRET (Virtual Reality Exposition Therapy)session associated with either active anodal tDCS or sham tDCS on the ventromedial prefrontal cortex to decrease anxiety related to visual height intolerance

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
28

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jun 2018

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 24, 2017

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 2, 2018

Completed
5 months until next milestone

Study Start

First participant enrolled

June 4, 2018

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 27, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 27, 2018

Completed
Last Updated

July 30, 2018

Status Verified

July 1, 2018

Enrollment Period

2 months

First QC Date

November 24, 2017

Last Update Submit

July 27, 2018

Conditions

Keywords

virtual realitybrain stimulation

Outcome Measures

Primary Outcomes (1)

  • Change in Subjective Units of Discomfort (SUD) at different heights

    Measure by 0 to 100 scale (100 being the most intense fear) subjective units of discomfort of subjects at different heights (corresponding to virtual floor of a flat) and at each visit

    within 2 weeks

Secondary Outcomes (6)

  • Change in composite score of Stress reactivity and intolerance of heights

    within one week

  • Change in physiologic effects

    within 2 weeks

  • Comparison in composite score of performance in virtual reality

    within 2 weeks

  • Debriefing

    within one week

  • Quality of immersion

    at 2 weeks

  • +1 more secondary outcomes

Study Arms (2)

VR + active brain stimulation

EXPERIMENTAL

Exposure to a virtual reality world with active transcranial electric stimulation

Device: VR + active brain stimulation

VR + sham brain stimulation

SHAM COMPARATOR

Exposure to a virtual reality world with sham transcranial electric stimulation

Device: VR + sham brain stimulation

Interventions

Active Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)

VR + active brain stimulation

Sham Brain stimulation (tDCS) is applied during exposition to virtual reality (20 minutes)

VR + sham brain stimulation

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Without any particular ethnic and psychosocial criteria
  • Subjects with fear of heights (anxiety AQ score \>45 and/or VHI score \>7)
  • Subjects with SUD score\>50/100 assessed during first visit
  • Subjects without psychiatric or addictive disorders
  • Subjects without criteria of phobia according to DSM5 (Diagnostic Statistical Manual)

You may not qualify if:

  • contraindication to tDCS (neurosurgical history, intracranial device, skin problems)
  • current virtual reality intolerance
  • history of psychiatric or addictive disorders
  • Use of psychotropic drugs
  • Use of non psychotropic treatments significantly influencing mood or level of anxiety
  • Neurological pathology, locomotor disability, or sensory (vestibular, visual, auditory ...)
  • pregnant or breast-feeding women

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital

Nantes, France

Location

MeSH Terms

Conditions

Acrophobia

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 24, 2017

First Posted

January 2, 2018

Study Start

June 4, 2018

Primary Completion

July 27, 2018

Study Completion

July 27, 2018

Last Updated

July 30, 2018

Record last verified: 2018-07

Locations